Osteoporosis medical therapy

Revision as of 15:42, 10 August 2017 by Eiman (talk | contribs)
Jump to navigation Jump to search

Osteoporosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Osteoporosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Life Style Modification
Pharmacotherapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Osteoporosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Osteoporosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Osteoporosis medical therapy

CDC on Osteoporosis medical therapy

Osteoporosis medical therapy in the news

Blogs on Osteoporosis medical therapy

Directions to Hospitals Treating Osteoporosis

Risk calculators and risk factors for Osteoporosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Raviteja Guddeti, M.B.B.S.[3]

Overview

Drugs, especially bisphosphonates are the main medications in the treatment of osteoporosis. However, lifestyle changes are also emphasized. No treatment can completely reverse established osteoporosis. Medical management can only halt the progression of the disease process.

Osteoporosis medical therapy

  • The mainstays of treatment in primary osteoporosis disease are based on change in life style, including:
    1. Fall avoidance
    2. Weight bearing exercises
    3. Adequate vitamin D and calcium consumption
  • Most of the time in high risk patients and people with past history of osteoporotic fracture, medical therapy is necessary.[1]

Medical therapy purpose

  • The primary most important goal for treatment of osteoporosis is to reduce longtime fracture risk in patients. Increasing bone mineral density (BMD) in response to the treatment is far less important than improvement of clinical aspects of osteoporosis, i.e., osteoporotic fracture. Therefore, most of the drugs' efficacy are measured by the extend they improve the fracture risk, in turn of increasing BMD.[2]
  • It has to explain for patients that treatment purpose is to reduce their fracture risk in the future. During the treatment, if a single fracture happened, it is not necessarily reflect of treatment failure; despite the major complicates fractures that may need to start alternative treatments or patient referral to specialist.[3]
  • Calcium and vitamin D supplementation have been found to be effective in reducing the long term fracture risk, significantly. In order to suggest the people to use vitamin D and calcium supplements, first the physician has to become sure that patient is not able to obtain the nutrients through daily intake. The available supplemental ions of calcium include calcium carbonate and calcium citrate; and vitamin D3 has various dosage forms.[4]

Medical therapy candidates

  • The national osteoporosis foundation (NOF) declare that osteoporosis treatment has to prescribed for followings:
    1. Elder men and postmenopausal women with past history of osteoporotic fracture
    2. Elder man and postmenopausal women with BMD-identified osteoporosis (T-score ≤ -2.5 SD)
    3. Elder man and postmenopausal women with -1.0 > T-score > -2.5 SD with high risk of osteoporotic fracture
    4. Men with hypogonadism that testosterone therapy is contraindicated[3]

Medical therapy options

Bisphosphonates

Bisphosphonates are the first line treatment for osteoporosis disease. They are not indicated in people with severe renal function impairment; thus, it is important to check renal function and serum creatinine before prescription. These drugs have to taken orally with large amount of water, not laying down until two hours following consumption, due to high risk of esophagitis. Rare but serious side effects may include osteonecrosis of jaw and atypical femoral fractures.

  • Alendronate: it is frequently used to treat osteoporosis in men, postmenopausal women, and also in corticosteroid-induced osteoporosis. The dosing is 70mg weekly per oral. Alendronate reduces hip, vertebral, and non-vertebral osteoporotic fractures.
  • Risedronate: it is also used to treat Paget's disease. Risedronate decreases the bone mass loss. The dosing is 35mg weekly or 150mg monthly per oral. Also available in delayed release forms. The drug reduces vertebral fractures.
  • Ibandronate: it is used to treat osteoporosis only in postmenopausal women. The dosing is 150mg monthly per oral; or 3mg every 3 months through intravenous (IV) rout. Regarding that Ibandronate only reduced vertebral fractures and there is no evidence of non-vertebral fractures improvement, it is rarely prescribed.
  • Zoledronic acid: it is also used for bone destructions due to Paget's disease, multiple myeloma, and metastatic bone tumors. Most potent bisphosphonate that has a higher risk of osteonecrosis of jaw. The dosing is 5mg annually through IV route. Zolendronate reduces hip, vertebral, and non-vertebral osteoporotic fractures. Common adverse effects are flu-like symptoms and bone pain, especially presented with first dose.

Receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor

  • Denosumab: human monoclonal antibody designed to inhibit RANKL (RANK ligand), a protein that acts as the primary signal for bone removal. It is used to treatOsteoporosis in elder men and postmenopausal women. The dosing is 60mg subcutaneous every 6 months. Denosumab reduces hip, vertebral, and non-vertebral osteoporotic fractures. The major side effects are eczema and nausea. [5]
  • Romosozumab: human monoclonal antibody designed to sclerostin, blocking protein of canonical Wnt signaling bone formation pathway. It is used to prevent osteoporotic fractures in postmenopausal women. The dosing is 210mg subcutaneous monthly. Romosozumab reduces vertebral fractures.[6]

Selective estrogen receptor modulator (SERM)

  • Raloxifene: it is the second line treatment of osteoporosis in postmenopausal women, for both treatment and prevention. The dosing is 60mg daily per oral. Raloxifene reduces vertebral fractures up to 35%. The major side effects are DVT and hot flashes in young pre-menopausal women. It has shown efficacy in reducing the prevalence and incidence of invasive breast cancer, too.[7]

Parathyroid hormone and related peptide analogs

  • Teriparatide: human recombinant parathyroid hormone used to treat postmenopausal woman with osteoporosis at high risk of fracture or to increase bone mass in men with osteoporosis. Usually, it is used in patients who cannot tolerate the oral bisphosphonates. It is also approved for corticosteroid induced osteoporosis. The dosing is 20mcg subcutaneous daily, approved for less than 2 years use. Teriparatide reduces vertebral and non-vertebral fractures, but not reduced hip fracture. Common side effects include nausea, hypercalcemia, and hypercalciuria. However, patients with previous radiation therapy, paget's disease, or young patients should avoid this medication.
  • Abaloparatide: human recombinant parathyroid hormone used to treat postmenopausal woman with osteoporosis at high risk of fracture or to increase bone mass in men with osteoporosis. It has a shorter duration of action than teriparatide. The dosing is 80mcg subcutaneous daily, approved for less than 2 years use. Abaloparatide reduces vertebral and non-vertebral fractures. Common side effects are dizziness, headache, hypercalcemia, and hypercalciuria.[3]

Calcitonin

  • Calcitonin is a hormone that inhibit the function of osteoclasts and result in growing bone mass. On the other hand, it can stimulate the osteoblast and also inhibit sclerostin production. It is used for postmenopausal women with osteoporosis. The dosing is 100units subcutaneous daily; or 200units intrnasal daily. Calcitonin reduces vertebral fractures up to 30%. Common side effects are rhinitis, nausea, and flushing.[8]

References

  1. Minisola S, Cipriani C, Occhiuto M, Pepe J (2017). "New anabolic therapies for osteoporosis". Intern Emerg Med. doi:10.1007/s11739-017-1719-4. PMID 28780668.
  2. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002). "Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs". Am. J. Med. 112 (4): 281–9. PMID 11893367.
  3. 3.0 3.1 3.2 Ensrud KE, Crandall CJ (2017). "Osteoporosis". Ann. Intern. Med. 167 (3): ITC17–ITC32. doi:10.7326/AITC201708010. PMID 28761958.
  4. Bauer DC (2013). "Clinical practice. Calcium supplements and fracture prevention". N. Engl. J. Med. 369 (16): 1537–43. doi:10.1056/NEJMcp1210380. PMC 4038300. PMID 24131178.
  5. McClung MR, Lewiecki EM, Geller ML; et al. (2012). "Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial". Osteoporos Int. doi:10.1007/s00198-012-2052-4. PMID 22776860. Unknown parameter |month= ignored (help)
  6. Bandeira L, Lewiecki EM, Bilezikian JP (2017). "Romosozumab for the treatment of osteoporosis". Expert Opin Biol Ther. 17 (2): 255–263. doi:10.1080/14712598.2017.1280455. PMID 28064540.
  7. Lippuner K, Buchard PA, De Geyter C; et al. (2012). "Recommendations for raloxifene use in daily clinical practice in the Swiss setting". Eur Spine J. doi:10.1007/s00586-012-2404-y. PMID 22739699. Unknown parameter |month= ignored (help)
  8. Felsenfeld, A. J.; Levine, B. S. (2015). "Calcitonin, the forgotten hormone: does it deserve to be forgotten?". Clinical Kidney Journal. 8 (2): 180–187. doi:10.1093/ckj/sfv011. ISSN 2048-8505.

Template:WS Template:WH